StockNews.com Initiates Coverage on Sorrento Therapeutics (NASDAQ:SRNE)

Equities research analysts at StockNews.com assumed coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Up 90.9%

NASDAQ:SRNE opened at $0.00 on Friday. Sorrento Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.02.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.